Skip to content

Increased dose at parametrium using intensity modulated radiotherapy in locally advanced cervical cancer treated with 2D brachytherapy

The effect of parametrial simultaneous integrated boost on local control in locally advanced cervical cancer treated with 2D brachytherapy

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ANZCTR
Registry ID
ACTRN12624000211561
Enrollment
40
Registered
2024-03-01
Start date
2024-03-01
Completion date
2024-11-06
Last updated
2026-09-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

The aim of the present study is to evaluate efficacy and safety of dose escalation at parametrium using intensity modulated radiotherapy in cervical cancer patients treated with 2D brachytherapy. The study hypothesis is that increased dose to parametrium will improve disease control with acceptable treatment toxicity.

Interventions

Parametrial simultaneous integrated boost via linear accelerator using intensity modulated radiotherapy or volumetric modulated arc therapy, is delineated by a radiation oncologist and planned by a medical physicist. Prior to treatment delivery performed by radiotherapists, the plan is evaluated by the radiation oncologist. Dose for parametrial simultaneous integrated boost is 55 Gray (Gy) in 25 fractions (5 fractions per week), concomitant with whole pelvic radiation with dose of 50Gy. During a

Parametrial simultaneous integrated boost via linear accelerator using intensity modulated radiotherapy or volumetric modulated arc therapy, is delineated by a radiation oncologist and planned by a medical physicist. Prior to treatment delivery performed by radiotherapists, the plan is evaluated by the radiation oncologist. Dose for parametrial simultaneous integrated boost is 55 Gray (Gy) in 25 fractions (5 fractions per week), concomitant with whole pelvic radiation with dose of 50Gy. During and after external beam radiotherapy, brachytherapy is performed with total dose of 7Gy times 4, weekly. The total treatment time should not be more than 56 days. All the treatments are delivered in radiotherapy unit, Vajira Hospital, Bangkok, Thailand. To assess or monitor adherence or fidelity to the intervention, audit of medical records by principal investigator and/or secondary investigator is done. If there is any protocol deviation, the issue will be discussed and informed to the subject(s) involved in order to maintain or improve fidelity.

Sponsors

Vajira hospital
Lead SponsorHospital

Study design

Allocation
Non-randomised trial
Intervention model
Single group
Primary purpose
Treatment
Masking
Open (masking not used)

Eligibility

Sex/Gender
All
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

squamous cell carcinoma, adenocarcinoma or adenosquamous cell carcinoma of uterine cervix FIGO stage IB3-IVa with/without inguinal node metastases aged at least 18 years ECOG 0-2

Exclusion criteria

-other primary malignancies except carcinoma in situ of cervix and basal cell carcinoma of skin -previous hysterectomy -previous pelvic or abdominal radiotherapy

Outcome results

None listed

Source: ANZCTR · Data processed: Sep 19, 2026